Viral hepatitis treatment as prevention (TAP)

Part I: 15 October 2020 – 16H30 until 19H30

Part II: 22 October 2020 – 16H30 until 19H30

Draft MEETING agenda
Meeting practical's

- Due to time constraints, the presentations were not pre-recorded
- All speakers will present 15 minutes

To facilitate the discussion
  - Switch on your camera

Mute yourself when you don’t speak
Meeting practicals

• Introduce yourself shortly when you intervene

• If you would like to speak up, you can either:
  • Physically raise your hand so it is visible on screen.
  • Use the ‘raise your hand’ button
    » Open participants list
    » In right column “raise hand”
VHPB

• Viral Hepatitis Prevention Board
• Viral hepatitis expert board — for more than 28 years
• Mission statement

The objective of VHPB is to contribute to the control and prevention of viral hepatitides
> All activities are in line with viral hepatitis elimination goals defined by WHO Global strategy
> Focus audiences are, in first instance, opinion leaders, policymakers, public health and health care professionals

• More info www.vhpb.org
Agenda

• Part I: **Treatment As Prevention (TAP) hepatitis C in risk groups**

• Part II: **Treatment as to prevent perinatal mother to child transmission (MTCT) of hepatitis B – Liver disease progression**

Next week: 22 October 2020
Meeting Objectives

- Viral hepatitis treatment as prevention (TAP) in Risk groups
  - Review scientific evidence of TAP to avoid hepatitis C infections in risk populations,
  - Discuss Real-life data of TAP project in different risk groups
  - Discuss the possible impact of treatment as prevention of WHO viral hepatitis elimination goals.
Agenda Treatment As Prevention (TAP) hepatitis C in risk groups

- **Session I**: Real-life data of TAP in different risk groups
  - 15 min presentation

- **Session 2**: Discussion session
  1. Is there enough scientific evidence to include TAP in hepatitis prevention guidelines in all risks group or in some?
  2. Should TAP be included in the national hepatitis elimination plan? (responsibilities – resources)
  3. Should TAP in risks groups be included in WHO’s targets to achieve hepatitis Elimination by 2030? Is Micro elimination the way to go?
Tour de table
Introduction of participants

• Introduce your self shortly